%0 Journal Article
%A Becker, Jürgen
%A Lodde, Georg
%A Haist, Maximilian
%A Ugurel, Selma
%T Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade.
%J Journal for ImmunoTherapy of Cancer
%V 14
%N 1
%@ 2051-1426
%C London
%I BioMed Central
%M DKFZ-2026-00104
%P e014090
%D 2026
%Z #DKTKZFB26#
%X Merkel cell carcinoma (MCC) exemplifies the paradigm of immunogenic tumors that nonetheless develop sophisticated immune evasion mechanisms. This is in line with the observation that MCC exhibits remarkable susceptibility to immune checkpoint inhibitors (ICIs), with responses in approximately half of patients with advanced disease in the first-line setting. However, 40-50
%K Humans
%K Carcinoma, Merkel Cell: drug therapy
%K Carcinoma, Merkel Cell: immunology
%K Immune Checkpoint Inhibitors: therapeutic use
%K Immune Checkpoint Inhibitors: pharmacology
%K Immunotherapy: methods
%K Skin Neoplasms: drug therapy
%K Skin Neoplasms: immunology
%K Adjuvant (Other)
%K Biomarker (Other)
%K Immune Checkpoint Inhibitor (Other)
%K Immunotherapy (Other)
%K Neoadjuvant (Other)
%K Immune Checkpoint Inhibitors (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41529910
%R 10.1136/jitc-2025-014090
%U https://inrepo02.dkfz.de/record/307633